ROSUVASTATIN FENOFIBRATE-INDUCED GASTROINTESTINAL DISTRESS: A CASE REPORT
International Journal of Advanced Research · 30.04.2026 · 14 (04) · 1485-1486
DOI: 10.21474/ijar01/23382 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Advanced Research, online erschienen am 30.04.2026. Verfasst von Neelam Rani und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background: The combination of rosuvastatin and fenofibrate is highly effective for mixed dyslipidemia but is associated with a range of gastrointestinal (GI) side effects. While nausea and vomiting are common, severe abdominal distension can mimic serious conditions like acute pancreatitis or hepatotoxicity. Case Presentation: We report the case of a patient N.R. 49 years of female who presented with loss of apetite, persistent nausea, vomiting, and significant abdominal distension within a weeks time after initiating Rosuvas-F 10 (Rosuvastatin 10mg / Fenofibrate 160mg). Laboratory investigations were performed to rule out systemic complications. Symptoms resolved promptly within 3-7 days of drug discontinuation (de-challenge).
Zitieren
APA
Rani, N., Bhagat, V., & Sharma, P. (2026). ROSUVASTATIN FENOFIBRATE-INDUCED GASTROINTESTINAL DISTRESS: A CASE REPORT. International Journal of Advanced Research, 14(04), 1485-1486. https://doi.org/10.21474/ijar01/23382
Vancouver
Rani N, Bhagat V, Sharma P. ROSUVASTATIN FENOFIBRATE-INDUCED GASTROINTESTINAL DISTRESS: A CASE REPORT. International Journal of Advanced Research. 2026;14(04):1485-1486. doi:10.21474/ijar01/23382
BibTeX
@article{Rani2026,
author = {Rani, Neelam and Bhagat, Veenakshi and Sharma, Poonam},
title = {ROSUVASTATIN FENOFIBRATE-INDUCED GASTROINTESTINAL DISTRESS: A CASE REPORT},
journal = {International Journal of Advanced Research},
year = {2026},
volume = {14},
number = {04},
pages = {1485--1486},
doi = {10.21474/ijar01/23382}
}
EUVIMED